Shine Medical Technologies said last week that it raised another $18 million for the medical radioisotopes it makes.

Janesville, Wis.-based Shine Medical said the equity, options and warrants round logged its first sale April 26 and has a total goal of $30 million. Some 99 unnamed investors participated in the $18.1 million round, according to a regulatory filing.

In April 2017 Shine Medical raised $29.3 million in a debt-and-options round. The company developed a method to create molybdenum-99 without needing a nuclear reactor or weapons-grade, highly enriched uranium, according to its website.

In 2016 the U.S. Nuclear Regulatory Commission cleared the company to build a medical isotope manufacturing plant, the first clearance since 1960, according to the company.